High risk gestational trophoblastic diseases: Diagnosis and primary management with EMACO chemotherapy by Kadam R. Priyanka & Dave S. Pariseema
 
Asian Pac. J. Health Sci., 2015; 2(4):82-86                                               e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Priyanka and Pariseema     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(4):82-86 
www.apjhs.com      82 
 
 
High risk gestational trophoblastic diseases: Diagnosis and primary management with 
EMACO chemotherapy 
Kadam R. Priyanka*, Dave S. Pariseema 
Department of Gynaecology Oncology, Gujarat Cancer Research Institute, Ahmedabad, India 
 
ABSTRACT 
 
Gestational trophoblastic disease (GTD) is characterized by abnormal proliferation of pregnancy associated 
trophoblastic tissue with malignant potential. GTD covers a spectrum of tumors and tumor-like conditions and may 
occur in a benign form as hydatiform mole or as malignancy in the form of invasive mole or choriocarcinoma. 
Gestational trophoblastic neoplasms are now some of the most curable of all solid tumors, with cure rates >90% 
even in the presence of widespread metastatic disease. An analytical prospective study of 25 patients with high risk 
GTN who were evaluated from a period of June 2012 to Nov 2014 at our institute and diagnosis has been described 
in the paper 
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Introduction 
 
 
Gestational trophoblastic disease (GTD) is 
characterized by abnormal proliferation of pregnancy 
associated trophoblastic tissue with malignant 
potential. GTD covers a spectrum of tumors and tumor-
like conditions and may occur in a benign form as 
hydatiform mole or as malignancy in the form of 
invasive mole or choriocarcinoma. Gestational 
trophoblastic neoplasms are now some of the most 
curable of all solid tumors, with cure rates >90% even 
in the presence of widespread metastatic disease[1]. In 
patients with postpartum uterine bleeding and 
subinvolution, GTN should be considered along with 
other possible causes, such as retained products of 
conception or endomyometritis, primary or metastatic 
tumors of other organ systems, or another pregnancy 
occurring shortly after the first. Optimal therapy in this 
group of disease rests in the correct diagnosis, 
assessing their risk for malignant behavior using 
prognostic scoring systems and administering 
appropriate treatment. Their rarity makes it imperative 
that these patients are treated in special centers by 
experts.  
Materials and methods 
This is an analytical prospective study of 25 patients  
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with high risk GTN who were evaluated from a period 
of June 2012 to Nov 2014 at our institute. 
Initialevaluation of each patient was done. This 
included the age and the detailed history (particularly 
the obstetric history including months of amenorrhoea, 
number of deliveries, the antecedent pregnancy, 
evacuation for mole and any chemotherapy 
administered). The investigations were sent which 
included CBC, RFT, LFT, and serum beta HCG level.  
Physical and radiological investigations (chest x-ray, 
ultrasonography, CT thorax, CT abdomen pelvis, MRI 
brain) were done. Then the FIGO 2000 staging was 
done for scoring and treatment. The patient having 
score =>7 and stage 2 or more was considered as high 
risk and patients with EMACO as primary management 
were included under the study. Those patients were 
also included who were already under treatment/ 
follow up during the period of study. During 
chemotherapy patients were evaluated for response in 
the form of β HCG level prior to each chemotherapy 
and partial response/ non responders and untoward 
effects were noted. Toxicity of chemotherapy were 
analysed according to WHO criteria. Follow up 
information were noted until year 2014 and efficacy of 
EMACO were seen by observing remission rate (fall in 
β HCG level).During each visit, patient’s complaints, 
menstrual history, contraception were noted. If patient 
conceived after remission, ultrasound was done to rule 
out recurrent vesicular mole or any abnormality. Β 
HCG was advised 6 weeks after delivery. 
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Result 
 
Twenty five cases of high risk GTN were studied at our 
institute from a period of June 2012 to November 2014 
.Mean age of the patients having high risk GTN was 
28.3 years. Maximum number of  cases were reported 
in 21-30 years of age group.In our study high risk GTN 
was common in lower socioeconomic class 
group(84%)and the highest incidence  was reported in 
multigravida patients (88%).Most common symptom 
was irregular vaginal bleeding (92%).Most common 
antecedent pregnancy was term pregnancy (44%) 
followed by abortion (40%) and molar pregnancy 
(16%).Most of the patients of  high risk GTN had β-
hCG level > 1 lakh(64%).Maximum number of patients 
of high risk risk GTN had FIGO 2000 scoring  < 10.All 
the patients of high risk GTN were given EMACO as 
primary management of chemotherapy. EMACO 
chemotherapy showed remission in 77% , resistance in 
23% of the patients and survival rate of 95%.Most 
common toxicity reported by EMACO chemotherapy 
was grade 1anaemia and grade 1febrile neutropenia 
followed by grade 1 oral mucositis.The number of 
patients who completed their one year of follow up 
after getting remission were 92%, out of these 2 
patients had uneventful pregnancy and none had 
recurrent molar pregnancy. Patients coming for follow 
up has normal menstrual period. 
 
Discussion 
GTD is diverse group of lesions that include placental 
villous abnormalities characterized by hydropic 
changes with abnormality in proliferation and 
maturation of trophoblast as well as neoplastic and non 
neoplastic proliferation of trophoblast unaccompanied 
by chorionic villi. In our study,mean age of the patients 
was 28.32 yrs. Youngest pt. was of 20 years of age and 
oldest was of 42 yrs. Number of cases were highest in 
21-30 yrs of age group. Our study results were 
comparable to study of Tertiary Hospital Sindh[2] 
.Maternal age is well established risk factor for GTN.  
Women > 35 years <20 years are at high risk[3].Most 
cases of GTN still occur in women under 35 years of 
age as most pregnant women are younger. Most 
common symptom was irregular vaginal bleeding 
which was found in 92% of the cases.  The results were 
comparable with the study of Hyatabad medical college 
study[4] (Table 14).
 
Nausea and vomiting was found in 
36% of the patients.  This could be because of high 
level of β-hCG level. Our study showed the term 
pregnancy as the most common antecedent pregnancy 
(44%). The interval from the antecedent pregnancy was 
< 2 months in 16% of the patients, 2-5 months in 40% 
of the patients and > 5 months  in 44% the patients.  In 
Tertiary Hospital Sindh study maximum patients were 
diagnosed between 2-5 months of duration of the 
antecedent pregnancy[5].Table 1 showed 64% patients 
who had  β hCG  level >1 lakh before starting the 
chemotherapy.  Trophoblastic disease with  initial  
levels  >1 lakh are at high risk of progression to 
neoplasm and  transformation is mainly detected by 
rising  hCG levels. In  our study, most of the patients 
presented in stage-III as shown in table 1. 
 
Table 1: Stage of the disease 
 
Stage   No. of cases(n) % 
I   2   8 
I            I   1   4 
I           II 20 80 
I           V   2   8 
 
Table 2: FIGO score, Most of the patients in our study had FIGO 2000 score < 10 
 Scoring   no. of cases (n)     % 
  <10 1       8 7   2 
 >10         7 2  8 
          
Table 3 showed lung metastasis  in 88% of the cases.  
The lung is the most common site of metastasis in cases 
of GTN. In many patients pulmonary lesions remain 
asymptomatic .The results of our study were consistent 
with Berkowith & Goldstein study.Although chest X ray 
usually demonstrates nodular metastasis, the pattern of 
metastasis disease can range from atelectatic area to 
subtle pleural abnormalities. A CT scan often is helpful in 
evaluating these non specific non specific areas which 
occurs in around 40% of the cases[6].Out of 25 patients, 
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3 patients were lost to follow up, 3 patients were still in 
follow up and 1 patient died. Out of remaining 18 
patients, 14 patients went into remission and 4 patients 
had resistance to EMACO chemotherapy. Figure 1 shows 
the graph of a patient who went into remission by 
EMACO chemotherapy. EMACO is the first line regimen 
use to treat high risk GTN as it has the best effectiveness 
to toxicity ratio.  In our study complete remission 
achieved in stage I – 100%, Stage II 100%, Stage-III – 
78%, stage IV – 0%. The addition of cisplatin (EMA-EP) 
may produce a slightly better remission rate (88%) when 
used as a first line therapy, but it is associated with 
greater hematologic toxicity[7].As second line of therapy, 
EMA-EP has achieved complete response rate ranging 
from 67 to 75%[8].Out of the four patients who were 
EMACO resistant, two patients were given EMA-EP 
regimen and other two were given BEP regimen. EMA-
EP led to 100% response rate. Out of two patients who 
were given BEP regimen, one patient achieved remission 
while other is still on follow up and showing declining 
hCG levels. Figure 2 shows the graph of the patient who 
was EMACO resistant and achieved remission with BEP.  
The studies were comparable with J. Lurian study.  In his 
study, out of 9 resistant EMACO patients 3 patients were 
given EMA-EP and 6 given BEP got remission.  The 
authors therefore concluded that patients with persistent 
or recurrent GTN should be treated with drug 
combination employing a platinum agent and etoposide 
with or without bleomycin and ifosfamide 
[9].Combination chemotherapy is often administered 2-3 
wks interval and timely administration of chemotherapy 
is essential.  Unnecessary treatment delay and dose 
reduction lead to tumor resistance and treatment failure.  
Patients receiving combination chemotherapy should 
have serial hCG measurements.  After the first 
undetectable hCG,  level 2-4 additional chemotherapy 
course should be administered
 
to reduce the risk of 
relapse[1]. 
 
 
 
                              Fig 1 : Patient showed complete remission to EMACO chemotherapy 
 
Out of 25 patients, 3 patient were lost to follow up. Out 
of rest 22 patients, 1  patient died in our study due to 
drug induced hepatotoxicity. As described in Table 3, 
most common toxicity by EMACO chemotherapy was 
anaemia and  febrile neutropenia. Febrile neutropenia 
was seen in 11(44%) of the patients. These patients 
were treated with injectable antibiotics and granulocyte 
stimulating factors.  Next common toxicities was oral 
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mucositis which were  seen in 24%  of the 
patients.Liver toxicity seen in 3 patients, 1 patient died 
due to drug induced hepatotoxicity and other 2 patients  
became  HbsAg and HbeAg positive due to 
myelosuppression and repeated blood transfusion.  The 
EMACO chemotherapy to 1 patient changed to 
cisplatin and Gemicitabine due to drug induced 
hepatotoxicity.EMACO is used as the first line 
regularly in high risk GTN patients as it has the best 
effectiveness to toxicity ratio. 
Table 3: Lung metastasis in 88% cases 
 Grade 1 Grade 2 Grade 3 Grade 4 
Hematology     
 Febrile Neutropenia  10 1 0 0 
 Neutropenia    8 0 0 0 
 Anaemia  15 5 3 1 
 Thrombocytopenia    2 0 0 0 
 Oral Mucositis    1 4 0 0 
 Liver Toxicity    3 0 0 0 
 Alopecia    2 0 0 0 
 
On follow up,out of 14 patients which went into 
remission ,13 patients had completed one year follow 
up. After one year of  completion of  chemotherapy, 2 
patients had uneventful pregnancy and none had 
recurrent molar pregnancy.During follow up period 
patients reported anxiety for the fear of  recurrence and 
infertility. Patients had advised to avoid pregnancy for 
the first year after the completion of the chemotherapy 
and advised to used oral contraceptive pills during 
these period.  Patients who received only EMACO 
regimen resumed regular menstrual periods within 3 
months of completion of treatment while the patients 
who required change of chemotherapy in some other 
forms resumed the regular periods within 6 months. 
Conclusion 
Gestational trophoblastic disease is a fascinating group 
of pregnancy disorders characterised by abnormal 
proliferation of trophoblast, ranging from benign to 
malignant.Significant progress has been made over the 
past decades in the diagnosis and management of 
woman with GTN. GTN is a high curable disease. 
Low-risk disease is treated by single-agent 
chemotherapy while high-risk disease is treated by 
multi-agent chemotherapy. The preferred 
chemotherapy for high risk GTN is EMACO regimen 
and is highly effective, well tolerated and conserves 
fertility. Its toxicity is predictable and reversible. 
Proper management in the early stage strongly 
influences the outcome of the disease. Referral to a 
specialist centre is important to ensure proper 
monitoring and management. The presentation in 
advanced disease is not only because of socioeconomic 
problem and lack of awareness in patients but also due 
to lack of awareness in medical personnel. Lastly, it is 
well established that the diagnosis of GTN may have a 
significant emotional impact on the patient and her 
family. Therefore, it is vital that these women are 
followed by a multidisciplinary team, where the 
psychological impact of this diagnosis and its treatment 
can be addressed. This approach will ensure optimal, 
holistic care for women with GTN. 
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